BCL2 and plasma cell myeloma: Similar findings were observed in a phase I trial of venetoclax for multiple myeloma; venetoclax was particularly effective for patients with a translocation between chromosomes 11 and 14 (t11:14), which occurs in approximately 20% of patients and is associated with higher levels of BCL2 expression in relation to other BCL2 family proteins[96].